Key facts
- It has raised $666.0M across 2 recorded rounds; the latest was Early Stage VC ($15.0M) in Apr 2015.
- Notable investors include GV, SV Angel, Felicis, First Round Capital, Blackstone — 24 tracked in total.
- DNAnexus has filed 3 Form Ds with the SEC since 2009, most recently Apr 2015 ($15.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for DNAnexus
Funding rounds
2 roundsAbout DNAnexus
Developer of a biomedical informatics and data management platform designed to analyze DNA-sequencing data. The company's platform assists researchers across a spectrum of industries like biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia to accelerate their genomics programs globally, enabling commercial and academic medical researchers to visualize and analyze big data systems for DNA from a single, unified system.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2009
- Employees
- 280
- Website
- dnanexus.com/
- Ownership
- Privately Held (backing)
DNAnexus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DNAnexus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DNAnexus in its N-PORT filings yet. We sweep new filings monthly.